CTL 102-tretazicar

Drug Profile

CTL 102-tretazicar

Alternative Names: CTL 102; CTL-102-GDEPT; CTL102/CB1954; NTR-GDEPT

Latest Information Update: 10 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Birmingham
  • Developer Innovata
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Head and neck cancer; Liver cancer; Prostate cancer

Most Recent Events

  • 10 Jul 2007 Discontinued - Phase-II for Head and neck cancer in United Kingdom (Intratumoural)
  • 10 Jul 2007 Discontinued - Phase-II for Liver cancer in United Kingdom (Intratumoural)
  • 10 Jul 2007 Discontinued - Phase-II for Prostate cancer in United Kingdom (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top